{
    "Trade/Device Name(s)": [
        "Lumipulse G CA15-3",
        "Lumipulse G CA15-3 Immunoreaction Cartridges"
    ],
    "Submitter Information": "Fujirebio Diagnostics, Inc.",
    "510(k) Number": "K192524",
    "Predicate Device Reference 510(k) Number(s)": [
        "K042732"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "MOI"
    ],
    "Summary Letter Date": "August 5, 2020",
    "Summary Letter Received Date": "August 6, 2020",
    "Submission Date": "September 12, 2019",
    "Regulation Number(s)": [
        "21CFR866.6010"
    ],
    "Regulation Name(s)": [
        "Tumor-Associated Antigen Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "CA 15-3",
        "Cancer antigen 15-3"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Sodium heparin tube",
        "Lithium heparin tube",
        "Dipotassium EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "LUMIPULSE G System",
        "LUMIPULSE G1200 System"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent Enzyme Immunoassay (CLEIA)",
        "Two-step sandwich immunoassay"
    ],
    "Methodologies": [
        "Quantitative immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "Reagent",
        "Cartridge"
    ],
    "Document Summary": "FDA 510(k) summary for Lumipulse G CA15-3 quantitative chemiluminescent enzyme immunoassay for CA 15-3 on LUMIPULSE G System",
    "Indications for Use Summary": "Aid in the management of patients previously diagnosed with stage II and III breast cancer; serial testing for CA15-3 values to be used in conjunction with other clinical monitoring methods; not for cancer screening or diagnosis.",
    "fda_folder": "Immunology"
}